Shire PLC (SHP) Receives Buy Rating from Bryan, Garnier & Co
Shire PLC (LON:SHP)‘s stock had its “buy” rating restated by Bryan, Garnier & Co in a research report issued to clients and investors on Monday. They currently have a GBX 6,900 ($85.40) target price on the biopharmaceutical company’s stock. Bryan, Garnier & Co’s target price indicates a potential upside of 33.44% from the stock’s current price.
Other analysts have also issued reports about the company. HSBC lowered their target price on Shire PLC from GBX 5,250 ($64.98) to GBX 5,200 ($64.36) and set a ” hold” rating for the company in a research note on Wednesday, September 28th. Deutsche Bank AG restated a “buy” rating and issued a GBX 6,000 ($74.26) target price on shares of Shire PLC in a research note on Wednesday, July 13th. Liberum Capital restated a “buy” rating and issued a GBX 5,500 ($68.07) target price on shares of Shire PLC in a research note on Tuesday, July 12th. Goldman Sachs Group Inc. restated a “buy” rating and issued a GBX 6,300 ($77.97) target price on shares of Shire PLC in a research note on Tuesday, July 12th. Finally, Berenberg Bank restated a “buy” rating and issued a GBX 5,800 ($71.78) target price on shares of Shire PLC in a research note on Wednesday, July 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eighteen have issued a buy rating to the company’s stock. Shire PLC has an average rating of “Buy” and a consensus price target of GBX 5,907.50 ($73.11).
Shire PLC (LON:SHP) opened at 5128.00 on Monday. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00. The stock has a 50 day moving average price of GBX 5,005.03 and a 200-day moving average price of GBX 4,600.81. The firm’s market cap is GBX 35.01 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/shire-plc-shp-receives-buy-rating-from-bryan-garnier-co.html
The business also recently announced a dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 8th were issued a dividend of GBX 3.51 ($0.04) per share. This represents a yield of 0.07%. The ex-dividend date was Thursday, September 8th.
In related news, insider Dominic Blakemore bought 133 shares of Shire PLC stock in a transaction on Friday, September 30th. The shares were purchased at an average price of GBX 5,010 ($62.00) per share, for a total transaction of £6,663.30 ($8,246.66).
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.